Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A.

[1]  J. Garber,et al.  Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. , 1991, The Journal of clinical endocrinology and metabolism.

[2]  P. Lønning,et al.  The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. , 1991, British Journal of Cancer.

[3]  D. Pompon,et al.  Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. , 1990, Cancer research.

[4]  R. Santen,et al.  The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. , 1990, The Journal of clinical endocrinology and metabolism.

[5]  M. Dowsett,et al.  POTENCY AND SELECTIVITY OF THE NON‐STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS , 1990, Clinical endocrinology.

[6]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[7]  R. Santen,et al.  A phase I trial of CGS 16949a. A new aromatase inhibitor , 1990, Cancer.

[8]  L. Dogliotti,et al.  Levels of eighteen non-conjugated and conjugated steroids in human breast cyst fluid: relationships with cyst type. , 1990, European journal of cancer.

[9]  M. Dowsett,et al.  Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. , 1990, Cancer research.

[10]  C. Mendelson,et al.  Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Matter,et al.  CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo. , 1988, Cancer research.

[12]  C. Mendelson,et al.  Regulation of estrogen biosynthesis by human adipose cells in vitro , 1987, Molecular and Cellular Endocrinology.

[13]  Leslie J. Browne,et al.  In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A , 1987, Steroids.

[14]  I. Mowszowicz,et al.  Increased aromatase activity in pubic skin fibroblasts from patients with isolated gynecomastia. , 1987 .

[15]  H. Matsumine,et al.  Aromatization by skeletal muscle. , 1986, The Journal of clinical endocrinology and metabolism.

[16]  M. Ghilchik,et al.  A comparison of the in vivo uptake and metabolism of 3H‐oestrone and 3H‐oestradiol by normal breast and breast tumour tissues in post‐menopausal women , 1986, International journal of cancer.

[17]  J. Deslypere,et al.  Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. , 1986, European journal of cancer & clinical oncology.

[18]  K. Davidson,et al.  THE RELATIONSHIP BETWEEN 17β‐HYDROXYSTEROID DEHYDROGENASE ACTIVITY AND OESTROGEN CONCENTRATIONS IN HUMAN BREAST TUMOURS AND IN NORMAL BREAST TISSUE , 1983, Clinical endocrinology.

[19]  S. Johnsen,et al.  Sex-hormone-binding globulin (SHBG) in serum in threatened abortion. , 1983, Acta endocrinologica.

[20]  G. H. Clowes,et al.  Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. , 1983, The New England journal of medicine.

[21]  T. Yamamoto,et al.  Multiple forms of aromatase and response of breast cancer aromatase to antiplacental aromatase II antibodies. , 1982, Cancer research.

[22]  R. Santen,et al.  A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. , 1981, The New England journal of medicine.

[23]  J. Fishman,et al.  Mechanism of estrogen biosynthesis. Participation of multiple enzyme sites in placental aromatase hydroxylations. , 1981, The Journal of biological chemistry.

[24]  R. Tremblay,et al.  Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. , 1974, Contraception.

[25]  W. Collins,et al.  Radioimmunoassay of oestrone and oestradiol in human plasma. , 1972, Acta endocrinologica.

[26]  H. Adlercreutz,et al.  Inhibition of aromatase with CGS 16949A in postmenopausal women. , 1989, The Journal of clinical endocrinology and metabolism.

[27]  A. Purohit,et al.  Oestrogen uptake and metabolism in vivo , 1989 .

[28]  V. Mahesh,et al.  Methods for multiple steroid radioimmunoassay. , 1975, Journal of steroid biochemistry.